News
4don MSN
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...
Pharmaceutical Technology on MSN17h
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costsNICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...
2don MSN
Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., ...
According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback